Back to top

Alnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic Partnerships

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $283....

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)